Cover Image
市場調查報告書

次發性副甲狀腺機能亢進 : 開發平台分析

Secondary Hyperparathyroidism - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 253669
出版日期 內容資訊 英文 57 Pages
訂單完成後即時交付
價格
Back to Top
次發性副甲狀腺機能亢進 : 開發平台分析 Secondary Hyperparathyroidism - Pipeline Review, H2 2016
出版日期: 2016年07月13日 內容資訊: 英文 57 Pages
簡介

次發性副甲狀腺機能亢進是由於鈣的顯著低下造成副甲狀腺過度分泌副甲狀腺素(PTH)的狀態,有骨骼變形、骨折、關節腫脹、慢性腎臟衰竭等症狀。治療方法有鈣受體激動劑及荷爾蒙補充療法等。

本報告涵括全球次發性副甲狀腺機能亢進治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品評估等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

次發性副甲狀腺機能亢進概要

治療藥的開發

  • 次發性副甲狀腺機能亢進開發中產品:概要
  • 次發性副甲狀腺機能亢進開發中產品:比較分析

次發性副甲狀腺機能亢進:正在開發的治療藥:各企業

次發性副甲狀腺機能亢進:開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

次發性副甲狀腺機能亢進:開發中的產品:各企業

次發性副甲狀腺機能亢進:開發治療藥的企業

  • Amgen Inc.
  • Deltanoid Pharmaceuticals Inc.
  • 田邊三菱製藥
  • Nektar Therapeutics
  • OPKO Health, Inc.

次發性副甲狀腺機能亢進:治療藥的評估

  • 單劑治療藥
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Calcifediol MR
  • Calcimimetic-18
  • CTA-091
  • CTAP-201
  • DP-001
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney 疾病 and Cancer
  • etelcalcetide
  • lunacalcipol
  • MT-4580
  • NKTR-228
  • VS-105
  • VS-110
  • VS-411
    • 產品概要
    • 作用機制
    • R&D的進展

最新的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 關注的新聞·新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8282IDB

Summary

Global Markets Direct's, 'Secondary Hyperparathyroidism - Pipeline Review, H2 2016', provides an overview of the Secondary Hyperparathyroidism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism
  • The report reviews pipeline therapeutics for Secondary Hyperparathyroidism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Secondary Hyperparathyroidism therapeutics and enlists all their major and minor projects
  • The report assesses Secondary Hyperparathyroidism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Secondary Hyperparathyroidism Overview
  • Therapeutics Development
    • Pipeline Products for Secondary Hyperparathyroidism - Overview
  • Secondary Hyperparathyroidism - Therapeutics under Development by Companies
  • Secondary Hyperparathyroidism - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Secondary Hyperparathyroidism - Products under Development by Companies
  • Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Deltanoid Pharmaceuticals Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • OPKO Health, Inc.
  • Secondary Hyperparathyroidism - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Calcimimetic-18 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTA-091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTAP-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DP-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etelcalcetide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lunacalcipol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MT-4580 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-411 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Secondary Hyperparathyroidism - Dormant Projects
  • Secondary Hyperparathyroidism - Discontinued Products
  • Secondary Hyperparathyroidism - Product Development Milestones
    • Featured News & Press Releases
      • May 24, 2016: ONO Announces Results from Phase 1/2 and Phase 3 Clinical Studies of "Etelcalcetide Hydrochloride (ONO-5163)" in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ERA-EDTA Congress
      • Jan 26, 2016: Investigational Agent Shows Promise for SHPT in Hemodialysis Patients
      • Jan 14, 2016: ONO Submits Manufacturing and Marketing Approval Application in Japan for "Etelcalcetide Hydrochloride" (ONO-5163), a Calcimimetic Agent, for Secondary Hyperparathyroidism in Patients on Hemodialysis
      • Dec 01, 2015: Kyowa Hakko Kirin Announces Commencement of Phase 3 Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
      • Nov 07, 2015: Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
      • Nov 06, 2015: FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
      • Sep 02, 2015: Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency
      • Aug 25, 2015: Amgen Submits New Drug Application For Novel Intravenous Calcimimetic Etelcalcetide
      • May 29, 2015: Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
      • Feb 25, 2015: Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis
      • Oct 15, 2014: Deltanoid's DP001 (2MD) pharmaceutical demonstrated safe and effective in kidney failure patients on dialysis
      • Aug 29, 2014: Kyowa Hakko Kirin Announces Commencement of Phase 2b Clinical Study of KHK7580 in Patients with Secondary Hyperparathyroidism in Japan
      • Aug 18, 2014: Amgen Announces Positive Top-Line Results From Second Phase 3 Study Of AMG 416 For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease Receiving Hemodialysis
      • Jan 06, 2012: KAI Pharmaceuticals Announces Initiation Of Second Phase II Study Of KAI-4169
      • Nov 14, 2011: KAI Announces Results from Phase II study of ONO-5163/KAI-4169, Calcium Sensing Receptor Agonist
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Secondary Hyperparathyroidism - Pipeline by Amgen Inc., H2 2016
  • Secondary Hyperparathyroidism - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016
  • Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Secondary Hyperparathyroidism - Dormant Projects, H2 2016
  • Secondary Hyperparathyroidism - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top